India · Delayed Price · Currency is INR Jubilant Pharmova Statistics
Total Valuation
NSE:JUBLPHARMA has a market cap or net worth of INR 178.22 billion. The enterprise value is 194.48 billion.
| Market Cap | 178.22B |
| Enterprise Value | 194.48B |
Important Dates
The next estimated earnings date is Friday, October 31, 2025.
| Earnings Date | Oct 31, 2025 |
| Ex-Dividend Date | Jul 25, 2025 |
Share Statistics
| Current Share Class | 158.40M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.33% |
| Shares Change (QoQ) | +0.23% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 63.42M |
Valuation Ratios
The trailing PE ratio is 38.73 and the forward PE ratio is 29.24.
| PE Ratio | 38.73 |
| Forward PE | 29.24 |
| PS Ratio | 2.41 |
| PB Ratio | 2.86 |
| P/TBV Ratio | 6.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 42.26 |
| EV / Sales | 2.63 |
| EV / EBITDA | 15.83 |
| EV / EBIT | 23.29 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.44 |
| Debt / EBITDA | 2.22 |
| Debt / FCF | n/a |
| Interest Coverage | 3.83 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 5.79% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 13.35M |
| Profits Per Employee | 829,638 |
| Employee Count | 5,547 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:JUBLPHARMA has paid 1.78 billion in taxes.
| Income Tax | 1.78B |
| Effective Tax Rate | 28.07% |
Stock Price Statistics
The stock price has increased by +10.44% in the last 52 weeks. The beta is 0.69, so NSE:JUBLPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.69 |
| 52-Week Price Change | +10.44% |
| 50-Day Moving Average | 1,131.04 |
| 200-Day Moving Average | 1,040.57 |
| Relative Strength Index (RSI) | 57.45 |
| Average Volume (20 Days) | 195,342 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:JUBLPHARMA had revenue of INR 74.04 billion and earned 4.60 billion in profits. Earnings per share was 28.97.
| Revenue | 74.04B |
| Gross Profit | 50.30B |
| Operating Income | 8.36B |
| Pretax Income | 6.35B |
| Net Income | 4.60B |
| EBITDA | 12.29B |
| EBIT | 8.36B |
| Earnings Per Share (EPS) | 28.97 |
Balance Sheet
The company has 10.89 billion in cash and 27.31 billion in debt, giving a net cash position of -16.42 billion.
| Cash & Cash Equivalents | 10.89B |
| Total Debt | 27.31B |
| Net Cash | -16.42B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 62.39B |
| Book Value Per Share | 395.41 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 67.94%, with operating and profit margins of 11.29% and 6.22%.
| Gross Margin | 67.94% |
| Operating Margin | 11.29% |
| Pretax Margin | 8.58% |
| Profit Margin | 6.22% |
| EBITDA Margin | 16.60% |
| EBIT Margin | 11.29% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 0.44%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 0.44% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.33% |
| Shareholder Yield | 0.11% |
| Earnings Yield | 2.58% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 17, 2006. It was a forward split with a ratio of 5.
| Last Split Date | Mar 17, 2006 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |